Amberlee D Hicks
Research Subjects
Research Interests
Amberlee D Hicks has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Rendon
Universidad Autonoma de Nuevo León, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Centro de Investigación, Prevención y Tratamiento de Infecciones Respiratorias (CIPTIR), Monterrey, Mexico
1 shared publication - Alyssa Schami
Population Health and Host Pathogen Interactions Programs, Texas Biomedical Research Institute, San Antonio, USA
1 shared publication - America M Cruz-Gonzalez
Departamento Estatal de Micobacteriosis, Secretaría de Salud de Tamaulipas
1 shared publication - Ashley Gay-Cobb
Population Health and Host Pathogens Interactions Programs
1 shared publication - Blanca I. Restrepo
School of Public Health, University of Texas Health Science Center at Houston, Brownsville, USA
1 shared publication - Carlton Aw Evans
IFHAD: Innovation For Health And Development
1 shared publication
Latest Publications
- Open Access
- 23 December 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (4) , e973-e980
Accuracy of the Phenotypic 1G Test to Detect Mycobacterium tuberculosis and Drug Resistance From Sputa in the US-Mexico Border
Background: With >10 million new tuberculosis (TB) cases per year, a limitation to TB control is the lack of simple and accurate tests for diagnosis and drug susceptibility testing (DST) in endemic regions. We evaluated the accuracy of the first-generation, low-complexity phenotypic TB test (1G test), designed for simultaneous Mycobacterium tuberculosis (Mtb) detection and resistance to isoniazid, rifampicin, and moxifloxacin, suitable for resource-limited settings. Methods: A cross-sectional study was conducted with sputa from 426 possible pulmonary TB cases from 2 small Mexican cities bordering Texas. The 1G test was compared against phenotypic TB detection tests in the region, specifically acid-fast bacilli smear microscopy and Mycobacteria Growth Indicator Tube (MGIT) culture, as well as MGIT-DST for resistance to isoniazid, rifampicin, and moxifloxacin. Results: The 1G test demonstrated ≥98% sensitivity for Mtb detection; 100% sensitivity and 91% (rifampicin), 94% (isoniazid), and 97% (moxifloxacin) specificity for DST; and less contamination than the MGIT (3.5% vs 8.1%, P < .05). The 1G test time to detection of Mtb and simultaneous DST was 17 days, while the MGIT-DST required 2 steps: 7 days for Mtb detection plus 14 more days for DST (21 days total). Our study site drug-resistant TB prevalence was 14% when testing all consecutively enrolled participants vs 6% by passive reporting. Conclusions: The 1G test is a low-complexity phenotypic TB diagnostic method that is a practical replacement to current culture-based tests. Future studies are warranted to evaluate implementation of the 1G test in decentralized clinics that lack molecular tools, resources, and expertise.
- 23 December 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (4) , e973-e980
Open AccessAccuracy of the Phenotypic 1G Test to Detect Mycobacterium tuberculosis and Drug Resistance From Sputa in the US-Mexico Border
Background: With >10 million new tuberculosis (TB) cases per year, a limitation to TB control is the lack of simple and accurate tests for diagnosis and drug susceptibility testing (DST) in endemic regions. We evaluated the accuracy of the first-generation, low-complexity phenotypic TB test (1G test), designed for simultaneous Mycobacterium tuberculosis (Mtb) detection and resistance to isoniazid, rifampicin, and moxifloxacin, suitable for resource-limited settings. Methods: A cross-sectional study was conducted with sputa from 426 possible pulmonary TB cases from 2 small Mexican cities bordering Texas. The 1G test was compared against phenotypic TB detection tests in the region, specifically acid-fast bacilli smear microscopy and Mycobacteria Growth Indicator Tube (MGIT) culture, as well as MGIT-DST for resistance to isoniazid, rifampicin, and moxifloxacin. Results: The 1G test demonstrated ≥98% sensitivity for Mtb detection; 100% sensitivity and 91% (rifampicin), 94% (isoniazid), and 97% (moxifloxacin) specificity for DST; and less contamination than the MGIT (3.5% vs 8.1%, P < .05). The 1G test time to detection of Mtb and simultaneous DST was 17 days, while the MGIT-DST required 2 steps: 7 days for Mtb detection plus 14 more days for DST (21 days total). Our study site drug-resistant TB prevalence was 14% when testing all consecutively enrolled participants vs 6% by passive reporting. Conclusions: The 1G test is a low-complexity phenotypic TB diagnostic method that is a practical replacement to current culture-based tests. Future studies are warranted to evaluate implementation of the 1G test in decentralized clinics that lack molecular tools, resources, and expertise.